Home > Resources > Whitepapers > Multivariate Data Analysis for Biotechnology and Bio-processing

Multivariate Data Analysis for Biotechnology and Bio-processing

Multivariate data analysis (MVA) and Design of Experiments (DoE) are advanced analysis techniques which enable biotech organizations to improve their data analysis and optimize operations across the product lifecycle. MVA and DoE are used in applications such as raw material assessment, analysis of clinical trial results, understanding and controlling fermentation processes, and improving quality control.

Spotlight

Grupo Alego

Grupo Alego is a Mexican group focused in clean energies, high-value oils, biolubricants and derivatives. We seek to preserve the environment through the use of state of the art eco-friendly technologies. Our dream is to build a sustainable legacy for future generations. We focus on contributing to the success of our customers and suppliers, surpassing their sustainability expectations through innovative products and high-quality services.

OTHER WHITEPAPERS

Recruitment, Retention & Diversity: The Evolution of Patient Engagement in Clinical Trials

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

70 years of wood modifcation with fungi

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

A Playbook for Emerging Biotechs

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment